Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study

This study evaluated 12‐week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir‐ and velpatasvir‐containing regimen. All 31 patients maintained a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruane, Peter, Strasser, Simone I., Gane, Edward J., Hyland, Robert H., Shao, Jiang, Dvory‐Sobol, Hadas, Tran, Tram, Stamm, Luisa M., Brainard, Diana M., Nyberg, Lisa, Shafran, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849811/
https://www.ncbi.nlm.nih.gov/pubmed/30663168
http://dx.doi.org/10.1111/jvh.13067
Descripción
Sumario:This study evaluated 12‐week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir‐ and velpatasvir‐containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.

Ejemplares similares